Eli Lilly Shows Its Strength at CIIE: Tirzepatide and Donanemab Take the Lead, Accelerating Full-Chain Localization

Eli Lilly Shows Its Strength at CIIE: Tirzepatide and Donanemab Take the Lead, Accelerating Full-Chain Localization

```

The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, 2025. Multinational pharmaceutical company Eli Lilly has made another appearance, with its booth theme "Innovative Journey, Infinite Future" and a design inspired from "8" to "∞", clearly reflecting this century-old pharmaceutical company's long-term commitment to China.

Through Lilly's booth, its clear strategic focus can be seen: using its globally most competitive blockbuster pipeline to precisely target China's most severe public health challenges, and establishing a firm foothold for the future through deep “localization of the entire industry chain.”

"Trump Card" Pipeline Takes Precise Positions

The core of Lilly's presentation this time is its "trump card" products that have made waves in the global market.

In the cardiovascular and metabolic field, Tirzepatide injection is undoubtedly the focal point. This drug has been approved in China for type 2 diabetes, long-term weight management, and obstructive sleep apnea (OSA), allowing it to precisely cover China's vast population of people with diabetes and obesity.

In neuroscience, an "uncharted territory," Lilly holds the breakthrough Alzheimer's disease (AD) therapy Donanemab injection. This medicine fully embodies the "CIIE speed"—after its debut at last year's expo, it was approved in China just over a month later.

Additionally, Lilly has brought the oral SERD drug Imlunestrant for breast cancer, and Mirikizumab for inflammatory bowel disease (IBD), both pending approval in China. Their "debut appearance" is intended to warm up the market for subsequent access and commercialization.

Reshaping Perceptions: From Public Issues to Healthcare Market

Complementing the products are two interactive experience zones carefully designed by Lilly, aiming to reshape public perception of two major diseases—driven by significant market potential.

  • Alzheimer's Disease (AD): Aiming at "healthy aging", Lilly set up a "Memory Café" and exhibited the charity artwork "Disturbed Time". In the background, China currently has nearly 17 million people with AD and other dementias. Lilly's move is meant to raise public awareness of early AD symptoms and promote "early diagnosis and treatment," clearly paving the way for its AD drug Donanemab.
  • Obesity: In response to the "Year of Weight Management," Lilly launched the "Body Resistance Decoding Exhibit." The core of this exhibition is to break the stereotype that "failure to lose weight is due to weak willpower," highlighting that obesity is a chronic disease with complex physiological mechanisms such as "metabolic adaptation." With the rate of overweight and obesity among Chinese adults reaching 50.7%, medicalizing obesity is a key step to unlocking the market potential of weight-loss drugs like Tirzepatide.

Localization Enhancement: From R&D and Manufacturing to Incubation

If blockbuster products are the “bullets,” then Lilly's full-chain layout in China is the “arsenal.” Deheran, Vice President of Lilly Group and General Manager of China, stated outright that the CIIE has a strong "spillover effect" and Lilly will continue to "enhance" its investment in the Chinese market.

"Enhancement" is reflected in substantial investments and strategic arrangements:

  1. Manufacturing: In October 2024, investing RMB 1.5 billion to upgrade the Suzhou factory, dedicated to expanding production capacity for innovative drugs in type 2 diabetes and obesity.
  2. R&D: In October 2024, establishing the China Medical Innovation Center in Beijing to improve clinical trial efficiency.
  3. Incubation: After operating the Beijing Innovation Incubator in March 2025 (Lilly's first incubation platform outside the US), Lilly announced at this CIIE the establishment of the Shanghai Innovation Incubator.

From R&D, clinical trials, manufacturing to commercialization, Lilly’s cumulative investment in China has now exceeded RMB 20 billion. Through this “set of combined punches,” Lilly is transforming from a simple product introducer into a deeply localized co-builder in “Healthy China” initiatives, aiming to ensure that its innovative drugs can “rapidly land” and “take root for the long term” in the Chinese market.

Risk Disclaimer and Limitation of LiabilityThe market has risks, investments should be made cautiously. This article does not constitute personal investment advice, nor does it take into account the special investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular situations. Investment based on this is at your own risk. ```